Clinical Trial Update: Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating lenalidomide after donor stem cell transplant with bortezomib in high-risk multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 1 | Status: TERMINATED